kirim

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of kirim

Kirim is a prescription-only medicine primarily defined by its active ingredient, Bromocriptine, a substance used for its neurochemical modulating effects. The drug is administered orally and functions by influencing key signaling pathways in the central nervous and neuroendocrine systems.

Property Description
Active ingredient Bromocriptine (as mesylate salt)
Form Oral tablet or capsule
Pharmacological class Dopamine Receptor Agonist, Ergot Derivative
Common use Modulating prolactin levels and dopamine activity
Origin Semisynthetic

What Type of Medication is Kirim (Bromocriptine)?

Kirim is pharmacologically classified as a Dopamine Receptor Agonist, which means the active substance, Bromocriptine, selectively stimulates the D2 subtype of dopamine receptors in the body. Chemically, it is identified as an Ergot Alkaloid Derivative, being a semisynthetic compound that is chemically modified from the natural substance ergocryptine. This classification characterizes the medicine’s role within a group of compounds used for regulating neurochemical function.

Composition, Form, and Unique Features

Kirim is manufactured as a single-ingredient product, containing only Bromocriptine mesylate within its solid oral form, available as either a tablet or a capsule. While Bromocriptine is available in standard formulations for endocrine disorders, a distinct quick-release (QR) formulation of the mesylate salt exists to target metabolic activity at a low dose. This difference in release profile represents a specific pharmacological feature designed to influence central dopaminergic tone.

Primary Purpose and Physiological Action

The fundamental purpose of Kirim is to normalize essential hormonal and neurochemical controls. Its core action is the enhancement of the inhibitory signal transmitted by dopamine, which results in the inhibition of prolactin secretion from the anterior pituitary gland. This regulatory capability identifies the drug as a tool for addressing physiological imbalances associated with elevated prolactin levels or deficient dopamine activity.

Regulatory References

  1. Bromocriptine: Uses, Dose, Mechanism, Side Effects
  2. Quick-release Bromocriptine for Type 2 Diabetes

What side effects are possible with kirim?

Possible Side Effects and Safety Information

Kirim (mifepristone) is a cortisol receptor blocker primarily indicated for Cushing's syndrome with associated hyperglycemia. Awareness of potential side effects and safety precautions is essential for proper use.

Common Side Effects

The most frequently reported side effects are generally manageable and may include:

  • Gastrointestinal: Nausea, vomiting, diarrhea, abdominal discomfort.
  • General: Fatigue, headache, joint pain, peripheral edema (swelling of hands, feet, or lower legs).
  • Reproductive (in women): Endometrial thickening or unexpected vaginal bleeding/spotting.

Serious Side Effects and Warnings

Pregnancy Termination Risk: Mifepristone is a potent antagonist of progesterone and can cause the loss of a pregnancy. Females of reproductive potential must have a negative pregnancy test before starting treatment and use non-hormonal contraception during therapy and for one month after the last dose.

Hypokalemia: Kirim can lead to or worsen low potassium levels in the blood (hypokalemia), which can cause fatigue, muscle weakness, or irregular heart rhythms. Regular monitoring of electrolytes is required.

Adrenal Insufficiency: Stopping Kirim suddenly or adjusting the dose without medical supervision can lead to adrenal insufficiency. Symptoms may include severe weakness, fatigue, nausea, vomiting, or dizziness.

Cardiac Effects: This medication may cause changes to the heart's electrical activity, specifically QT interval prolongation. Patients with pre-existing heart conditions should use it with caution.

Drug Interactions: Kirim is metabolized by the CYP3A enzyme system and can significantly affect the levels of other medications, potentially leading to serious adverse events. It is vital to inform a healthcare provider of all medications and supplements being taken.

Overdose and Emergency Response

Overdose and When to Seek Help: Regulatory Profile

This section outlines the officially documented overdose manifestations and required emergency actions for Kirim (Bromocriptine), based strictly on government regulatory prescribing information.


Documented Overdose Manifestations

Officially documented clinical signs and symptoms reported in overdose situations are primarily related to excessive dopamine activity. These effects include:

  • Gastrointestinal Distress: Nausea and vomiting.
  • Central Nervous System Effects: Somnolence (drowsiness).
  • Cardiovascular Risk: The most severe complication is severe hypotension (a serious drop in blood pressure), which requires urgent clinical attention.

Emergency Actions and Management

Regulatory documents emphasize that management is supportive and symptomatic, as no specific antidote is officially listed for Bromocriptine overdose.

Category Regulator-Documented Action
Urgent Help Seek immediate medical attention for any suspected overdose.
Key Management Treatment is symptomatic; the priority is the management of severe hypotension.
Supportive Steps Supportive measures should be employed, which may include the use of activated charcoal to reduce absorption.
Antidote Status No specific antidote is officially documented.

Summary of Regulatory Constraints

The official overdose profile is defined by the requirement to monitor and manage severe hypotension, which necessitates urgent clinical care. This mandate to seek immediate medical attention is the critical action driven by the officially documented severity of the cardiovascular risk.

Therapeutic Uses of kirim

What Kirim Treats: Main Uses and Benefits

Kirim is commonly used to manage conditions stemming from elevated levels of the hormone prolactin (hyperprolactinemia), which includes prolactin-secreting pituitary tumors (prolactinomas). This therapeutic domain addresses symptom groups like abnormal milk discharge (galactorrhea), the absence of menstrual periods (amenorrhea), and related infertility in both men and women. By addressing this underlying hormonal imbalance, the medication contributes to improved reproductive health and supports fertility potential.


The medication is considered relevant for easing symptoms in patients with Parkinson's disease, where it may assist in managing the symptom cluster of motor symptoms, including muscle rigidity, resting tremors, and overall slowness of movement (bradykinesia). It is applied in specific endocrine contexts for Type 2 Diabetes Mellitus and Acromegaly. In these situations, it is used to help manage elevated blood sugar levels and supports the easing of physical signs associated with growth hormone excess.

“The medication is considered relevant for easing symptoms that interfere with daily comfort across multiple domains, supporting patients during episodes of heightened discomfort.”

Quick Fact: Support for Prolactin-Related Symptoms Kirim is applied when appropriate for conditions involving systemic imbalance, assisting with the management of symptom groups that may appear suddenly or fluctuate.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Kirim (Bromocriptine)?

Population eligibility for Kirim is strictly defined by regulatory labeling based on physiological status, existing medical conditions, and age.

Absolute Contraindications (Prohibited Use)

Kirim is contraindicated and must not be used in the following patient populations, as specified in government documents:

  • Hypersensitivity: Patients with known allergy to Bromocriptine or other ergot alkaloids.
  • Hypertensive/Cardiovascular Risk: Individuals with uncontrolled hypertension, severe cardiovascular conditions (e.g., coronary artery disease), or hypertensive disorders of pregnancy (e.g., pre-eclampsia).
  • Lactation: Nursing women; use for routine suppression of breast milk production is not recommended by regulatory bodies (e.g., EMA) due to serious risks.
  • Other Comorbidities: Patients with Type 1 diabetes, diabetic ketoacidosis, or a history of syncopal migraine (for the quick-release formulation).

Eligibility Restrictions and Conditional Use

Use is restricted or requires caution in specific groups:

Population Group Eligibility Status
Pediatric Patients Safety and efficacy not established for most indications in children under 11 years; approved use is limited to prolactin-secreting adenomas in adolescents.
Geriatric Patients Caution is required; dose selection should be cautious due to a lack of sufficient data to determine differential response compared to younger adults.
Hepatic Impairment Use with caution is advised due to the drug’s extensive liver metabolism; safety is not established.
Renal Impairment Safety and effectiveness in severe renal impairment have not been established.

Pregnancy Status: Kirim is generally discontinued upon confirmation of pregnancy, though continuation is conditionally considered for rapidly expanding tumors under specialist guidance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

All medicines, including kirim, have the potential to interact with other medicinal products, supplements, or certain foods. These interactions can change how kirim works or increase the risk of side effects. While the full, official interaction profile for kirim must be reviewed by your healthcare provider, interactions generally fall into two categories: pharmacokinetic (PK) and pharmacodynamic (PD).

PK Interactions: These occur when a co-administered product affects how kirim is absorbed, metabolized, or eliminated from the body. Many medications are broken down by liver enzymes, specifically the cytochrome P450 (CYP) system. If kirim inhibits or induces a major CYP enzyme (such as CYP3A4), it may increase or decrease the blood levels of other drugs processed by that same enzyme, requiring potential dose adjustments.

PD Interactions: These result when two medicines have similar or opposing effects on the body. For example, combining kirim with other medicines that cause central nervous system (CNS) depression (e.g., certain sedatives or alcohol) could lead to excessive drowsiness. Similarly, combining it with medicines that affect heart rhythm (such as those prolonging the QT interval) could increase cardiac risks.

General Interaction Considerations

Interaction Type Examples of Affected Products/Classes
Pharmacokinetic Strong CYP enzyme inducers/inhibitors; P-gp substrates/inhibitors
Pharmacodynamic CNS depressants (alcohol, tranquilizers); QT-prolonging agents

Patients should always provide a complete list of all prescription and over-the-counter medicines, herbal products, and supplements to their doctor or pharmacist to screen for potential interactions before starting treatment with kirim.

Mechanism of Action

Central Neuroendocrine Signaling and Prolactin Suppression

Kirim (Bromocriptine) operates primarily by functioning as an agonist at the Dopamine D2 Receptors (D2R), particularly those located on the lactotroph cells within the anterior pituitary gland. This interaction initiates an inhibitory G-protein signaling cascade, which reduces intracellular levels of the secondary messenger cAMP. This molecular event suppresses the cellular processes responsible for hormone production. This mechanism results in the physiological suppression of prolactin secretion, mimicking the inhibitory signal of endogenous dopamine.


Hypothalamic Pathway Modulation and Functional Constraints

The drug also modulates the central nervous system (CNS) by influencing neurotransmitter activity in the hypothalamus. This action is hypothesized to modulate sympathetic signaling, thereby altering the central control over peripheral metabolism. This modulation of autonomic balance contributes to alterations in insulin signaling and glucose/lipid homeostasis throughout the body. Kirim also exhibits antagonism at D1 and alpha2-adrenergic receptors, which influences central motor pathway function, though this co-activity defines mechanistic constraints on its primary D2 receptor effect.

Dosage and Administration Information

Administration Protocol for Kirim (Bromocriptine)

Kirim is administered exclusively via the oral route, available as a standard-release tablet or capsule and a distinct 0.8 mg quick-release tablet. Correct use is defined by three key components: indication-specific dosing, mandatory timing with food, and a required titration schedule.

Dosing and Schedule

Indication Initial Dose Maintenance Range Frequency
Hyperprolactinemia 1.25 mg to 2.5 mg once daily 2.5 mg/ day to 15 mg/ day Once daily, then divided doses
Parkinson's Disease 1.25 mg twice daily 10 mg/ day to 30 mg/ day Divided doses
Type 2 Diabetes (QR) 0.8 mg once daily 1.6 mg/ day to 4.8 mg/ day (Maximum) Once daily

The initiation of therapy is characterized by a gradual dose increase, or titration, which varies in rate depending on the condition being addressed. For the quick-release formulation, the dose is increased by 0.8 mg increments weekly, while standard release regimens involve increasing the dose by 2.5 mg every 2 to 7 days.

Contextual Use Rules

All forms of the medicine must be taken with food to manage patient tolerance. For the quick-release formulation, the protocol involves taking the dose within two hours after waking in the morning. In cases where a morning dose is missed, the usual dose is resumed the following morning, and the dose is not doubled.

Specific dosage considerations are noted for certain groups, including a caution for older adults, who typically begin treatment at the lower end of the dose range, and for patients with hepatic impairment, who may require dose adjustment.

Recent Clinical Evidence

Research evidence / Overview of Studies for Kirim

The research base for Kirim (Bromocriptine) has been explored through various clinical study designs, including randomized controlled trials (RCTs), comparative studies, and long-term observational data. These studies were conducted to explore outcomes and changes in specific biomarkers and functional measures across its authorized uses.


1. Evidence for use in Hyperprolactinemia-Associated Dysfunctions

Research has extensively explored the medicine's use for conditions associated with high prolactin levels. Studies focused on measuring changes in serum prolactin levels and monitoring changes in the size of prolactin-secreting tumors (prolactinomas). Trials documented patterns where the medicine was associated with a measured decrease in prolactin levels in the observed populations. Research also explored the relationship between the medicine and changes in the size of these tumors. Consistent data on outcomes after stopping treatment are mixed, and evidence for children younger than 16 years is limited.


2. Evidence for use in Parkinson's Disease (Adjunctive Therapy)

Kirim was evaluated in the context of Parkinson's disease, primarily as an add-on treatment alongside Levodopa therapy. Randomized trials measured changes in motor symptoms and functional activity levels. Findings from comparative studies suggest that when Kirim was used in combination with Levodopa, some trials documented the use of lower doses of Levodopa while motor scores were being measured. Long-term studies reported that the combination therapy was associated with patterns of difference in the incidence of certain motor complications when compared to Levodopa alone.


3. Evidence for use in Type 2 Diabetes Mellitus (Quick-Release Formulation)

Large, randomized, placebo-controlled trials investigated a specific quick-release formulation. These trials monitored changes in glycemic control biomarkers, specifically HbA1c levels, and tracked the rate of Major Adverse Cardiovascular Events (MACE). Studies reported measured changes in HbA1c levels and described patterns indicating measured differences in the rate of the MACE composite endpoint between the quick-release formulation group and the placebo group during the study period. Comparative evidence against all newer anti-diabetic medications is lacking.

Frequently Asked Questions (FAQ)

Common questions about kirim (FAQ)

Q: What is the main reason doctors prescribe kirim?

Official regulatory uses include treating high prolactin levels, certain pituitary tumors, symptoms of Parkinson's disease, and lowering blood sugar in Type 2 Diabetes with the quick-release formulation. These indications are based strictly on official approvals and prescribing information.


Q: What makes kirim different from other treatments?

The medicine is defined as a Dopamine D2 Agonist and an Ergot Derivative, placing it in a specific pharmacological class. Official information indicates that a unique quick-release formulation was specifically developed to target central neuroendocrine signaling for Type 2 Diabetes, a feature that helps define its utility.


Q: Can kirim be used for other health issues besides the main one?

The medicine is officially approved by regulatory agencies for specific conditions, which are known as its indications. Discussion of use for conditions that are not officially approved, or off-label use, is restricted in official documents.


Q: How quickly should I expect to notice kirim working?

Measurable effects on prolactin levels can begin within two hours of administration, and the maximal effect is often achieved within eight hours. This finding is based on the pharmacokinetic studies detailed in the official documents.


Q: Does kirim have to build up in the body to work?

The drug is extensively processed by the body's metabolism after administration. Pharmacokinetic data indicates that plasma concentrations typically reach their peak within one to three hours after administration.


Q: How long does the effect of one dose of kirim last?

Reduced prolactin concentrations can persist for at least four to five hours after a single dose of the medicine. The overall duration of action is influenced by its half-life and individual metabolism.


Q: Do the side effects of kirim usually go away over time?

Official regulatory safety reports indicate that some adverse effects, such as somnolence (drowsiness), have been reported to lessen or resolve over time in the majority of patients.


Q: Is it normal to feel [general side effect, e.g., tired] when starting kirim?

Common adverse reactions, including fatigue, nausea, and dizziness, are frequently reported in clinical trials. Official product information notes that these may be more noticeable when beginning treatment or when the dose is gradually increased (titration).


Q: Can kirim cause issues with [general organ, e.g., liver or kidney function]?

The medicine is extensively processed by the liver, and its elimination is mainly through the feces. Official warnings state that safety has not been established in patients with severe liver (hepatic) or kidney (renal) impairment, and caution is required in these populations.


Q: Can I stop taking kirim suddenly?

Official warnings indicate that sudden withdrawal of the drug, particularly after prolonged high-dose treatment, has been associated with a syndrome resembling Neuroleptic Malignant Syndrome.


Q: Does kirim interact with common over-the-counter pain relievers?

Interactions are possible with any medicine that affects the CYP3A4 enzyme system in the liver or has a similar effect on the central nervous system or blood pressure. Official product information notes that review of all concomitant medications by a healthcare professional is necessary to screen for potential risks.


Q: Are there any specific vitamins or supplements that interact with kirim?

Official labeling notes that concomitant use with strong CYP3A4 inhibitors (found in some supplements) requires caution or avoidance. This is because these substances can significantly increase the drug's concentration in the body, raising the potential for adverse effects.


Q: What types of food should be avoided while taking kirim?

While generally taken with food to manage tolerance, official warnings state that alcohol intake should be limited as it can worsen side effects like dizziness. Official documents recommend discussing specific dietary limitations, such as foods high in tyramine, with a healthcare professional.


Q: Can women who are planning to become pregnant use kirim?

Women of childbearing potential are generally advised to use a reliable, non-hormonal method of contraception while taking this medicine. The drug is typically discontinued once pregnancy is confirmed, though continuation may be conditionally considered by a specialist for rapidly expanding tumors.


Q: Can kirim affect my ability to drive or operate machinery?

Official product information states that the drug has been associated with somnolence (drowsiness) and, rarely, sudden sleep onset. Regulatory documents state that patients who experience these symptoms are advised not to drive or operate machinery.


Q: Does kirim contain [common allergen, e.g., gluten or lactose]?

Some formulations of the drug contain lactose monohydrate as an inactive ingredient (excipient). Official labeling notes that the medicine is strictly contraindicated in patients with known hypersensitivity to any of its excipients.


Q: Is kirim a controlled substance?

The drug is not classified as a controlled substance by regulatory bodies (CSA Schedule N/A). It is available only by prescription.


Q: Is there a generic version of kirim available?

A generic version of the active ingredient, bromocriptine mesylate, has been approved by regulatory agencies and is available.


Q: What research has been done on the long-term use of kirim?

Official documents indicate that long-term observational data has been explored in several indications, including Parkinson's disease. Additionally, long-term studies have tracked cardiovascular outcomes in patients using the quick-release formulation for Type 2 Diabetes.


Q: Where can I find the official prescribing information for kirim?

The official labeling and prescribing information can be found on regulatory websites. This includes information from the U.S. FDA website (DailyMed) or the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC).


Q: Does kirim affect sleep?

Official warnings indicate that the medicine may cause somnolence (drowsiness) and has been associated with rare episodes of sudden sleep onset. These effects are particularly noted in patients being treated for Parkinson’s disease.


Q: Does kirim make you gain weight?

Regulatory safety information does not list weight gain as a common or frequent side effect reported in clinical trials.


Q: Can kirim cause mood changes or depression?

Reports from clinical experience mention mental depression as a potential side effect. Furthermore, post-marketing reports for higher doses have noted psychotic disorders and hallucinations.


Q: What is the difference between a side effect and an allergic reaction to kirim?

Official labels list an allergic reaction (hypersensitivity) as an absolute contraindication, meaning the medicine should not be taken. An allergic reaction is typically a more severe and acute response than a common side effect.


Q: Does kirim interact with herbal teas?

Herbal products may be strong inhibitors or inducers of the CYP3A4 enzyme system. Official product information notes that concomitant use with known strong inhibitors requires caution or avoidance as this can increase the drug's concentration in the body.


Q: Do men and women experience kirim differently?

The regulatory label notes that the drug is contraindicated in nursing women and carries specific warnings (e.g., stroke, seizure) for women who have recently given birth. Reproductive side effects are also specified for women.


Q: Are there any black box warnings for kirim?

Regulatory documents for the bromocriptine quick-release formulation (Cycloset) do not contain a specific black box warning.


Q: How is kirim typically packaged or sold?

The medicine is typically sold in bottles containing a specific count of tablets or capsules (e.g., 30 or 100 units). It is always dispensed under a prescription-only status.


Q: Does kirim interact with hormonal birth control?

For women taking the medicine to treat hyperprolactinemia, official guidance indicates that hormonal contraceptives may not be fully effective until regular menstrual periods resume. Therefore, a non-hormonal method of birth control is often recommended initially.


Q: Why is kirim prescribed instead of [another common medicine]? (Descriptive)

In Parkinson's disease, the medicine has been evaluated as an add-on treatment to Levodopa therapy. Its quick-release formulation for Type 2 Diabetes has a unique mechanism of action focused on central neuroendocrine signaling.

How should kirim be stored and disposed of?

How to Store and Dispose of Kirim (Bromocriptine)

Kirim (bromocriptine) must be stored strictly according to the official labeling to maintain its stability and effectiveness.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, generally between 20 C to 25 C (68 F to 77 F).
Protection Must be protected from light and moisture and kept away from excessive heat.
Container Store in the original container and keep it tightly closed.
Child Safety Keep the medication out of the sight and reach of children at all times.

Disposal Instructions

Do not dispose of this medication by flushing it down a toilet or pouring it down a drain. The safest method for discarding unused or expired tablets is by utilizing an authorized drug take-back program. If a take-back program is unavailable, follow the procedure of mixing the medication with an undesirable substance (such as dirt or cat litter) in a sealed bag before placing it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of kirim found in:

A-Z Index: